Raiffeisen Bank International AG Buys New Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Raiffeisen Bank International AG purchased a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 150,000 shares of the company’s stock, valued at approximately $1,016,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in RXRX. Barclays PLC raised its stake in Recursion Pharmaceuticals by 53.9% in the third quarter. Barclays PLC now owns 697,432 shares of the company’s stock valued at $4,596,000 after buying an additional 244,278 shares during the last quarter. Wedmont Private Capital raised its stake in Recursion Pharmaceuticals by 10.6% in the fourth quarter. Wedmont Private Capital now owns 20,943 shares of the company’s stock valued at $144,000 after buying an additional 2,000 shares during the last quarter. Decker Retirement Planning Inc. purchased a new stake in Recursion Pharmaceuticals in the fourth quarter valued at about $26,000. Avanza Fonder AB purchased a new stake in Recursion Pharmaceuticals in the fourth quarter valued at about $580,000. Finally, Arkadios Wealth Advisors purchased a new stake in Recursion Pharmaceuticals in the fourth quarter valued at about $84,000. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on RXRX shares. Needham & Company LLC decreased their price target on Recursion Pharmaceuticals from $11.00 to $8.00 and set a “buy” rating for the company in a research note on Tuesday, May 6th. Cowen reiterated a “hold” rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Leerink Partners cut their price target on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating on the stock in a report on Friday, February 28th. Finally, Morgan Stanley decreased their price objective on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an “equal weight” rating for the company in a research note on Thursday, April 10th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $7.60.

Recursion Pharmaceuticals Trading Up 7.3%

Shares of RXRX opened at $4.56 on Friday. Recursion Pharmaceuticals, Inc. has a 52-week low of $3.79 and a 52-week high of $12.36. The stock has a market cap of $1.85 billion, a PE ratio of -2.98 and a beta of 0.99. The firm’s fifty day moving average is $5.34 and its two-hundred day moving average is $6.59. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings results on Monday, May 5th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business had revenue of $14.75 million for the quarter, compared to analyst estimates of $18.12 million. During the same quarter in the previous year, the firm posted ($0.39) earnings per share. The business’s revenue was up 7.2% compared to the same quarter last year. Research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.